Macrocycles

---

Expanding the reach of small-molecule drug discovery

Macrocycles represent one of the most exciting frontiers in modern drug discovery. By combining the favorable properties of traditional small molecules with the ability to engage larger, more complex protein surfaces, macrocycles enable the development of medicines against targets that have historically been difficult to drug. Their unique 3-dimensional architecture often results in exceptional potency, high target selectivity, improved metabolic stability, and prolonged target engagement, while retaining the potential for oral bioavailability.

At Cheminpharma, we leverage our extensive expertise in medicinal chemistry and macrocycle design to develop innovative therapeutics for oncology and other serious diseases. Our approach integrates structure-based drug design, computational modeling, and synthetic chemistry to create novel macrocyclic molecules with optimized pharmacokinetic and pharmacodynamic properties. We are particularly interested in applying macrocycle technology to challenging biological targets, including protein kinases, protein-protein interactions, and emerging therapeutic modalities such as targeted protein degradation. By expanding the boundaries of what small molecules can achieve, we aim to deliver next-generation medicines with meaningful benefits for patients.